{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:17:22Z","timestamp":1791328642882,"version":"4.3.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":2320,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01AI068741"],"award-info":[{"award-number":["1R01AI068741"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1038\/mt.2010.53","type":"journal-article","created":{"date-parts":[[2010,4,7]],"date-time":"2010-04-07T03:13:25Z","timestamp":1270610005000},"page":"1143-1154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Detrimental Effect of the Proteasome Inhibitor, Bortezomib in Bacterial Superantigen- and Lipopolysaccharide-induced Systemic Inflammation"],"prefix":"10.1016","volume":"18","author":[{"given":"Ashenafi Y","family":"Tilahun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayne E","family":"Theuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chella S","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govindarajan","family":"Rajagopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2010.53_bib1","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1600-065X.2008.00681.x","article-title":"The bacterial superantigen and superantigen-like proteins","volume":"225","author":"Fraser","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1038\/mt.2010.53_bib2","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0272-2712(18)30023-4","article-title":"Toxins as weapons of mass destruction. A comparison and contrast with biological-warfare and chemical-warfare agents","volume":"21","author":"Madsen","year":"2001","journal-title":"Clin Lab Med"},{"issue":"Suppl 2","key":"10.1038\/mt.2010.53_bib3","first-page":"S106","article-title":"Recognition and management of Staphylococcus aureus toxin-mediated disease","volume":"35","author":"Murray","year":"2005","journal-title":"Intern Med J"},{"key":"10.1038\/mt.2010.53_bib4","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0092-8674(94)90482-0","article-title":"The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B","volume":"78","author":"Palombella","year":"1994","journal-title":"Cell"},{"key":"10.1038\/mt.2010.53_bib5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1172\/JCI11914","article-title":"Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer","volume":"107","author":"Yamamoto","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1038\/mt.2010.53_bib6","doi-asserted-by":"crossref","first-page":"15671","DOI":"10.1073\/pnas.95.26.15671","article-title":"Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis","volume":"95","author":"Palombella","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2010.53_bib7","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2613.2006.00490.x","article-title":"Modulation of inflammatory response in sepsis by proteasome inhibition","volume":"87","author":"Safr\u00e1nek","year":"2006","journal-title":"Int J Exp Pathol"},{"key":"10.1038\/mt.2010.53_bib8","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1517\/17425255.4.5.639","article-title":"Bortezomib in multiple myeloma","volume":"4","author":"Terpos","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1038\/mt.2010.53_bib9","doi-asserted-by":"crossref","first-page":"8125","DOI":"10.4049\/jimmunol.174.12.8125","article-title":"Serum amyloid A-luciferase transgenic mice: response to sepsis, acute arthritis, and contact hypersensitivity and the effects of proteasome inhibition","volume":"174","author":"Zhang","year":"2005","journal-title":"J Immunol"},{"key":"10.1038\/mt.2010.53_bib10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1152\/physiolgenomics.90385.2008","article-title":"Early gene expression changes induced by the bacterial superantigen staphylococcal enterotoxin B and its modulation by a proteasome inhibitor","volume":"37","author":"Rajagopalan","year":"2009","journal-title":"Physiol Genomics"},{"key":"10.1038\/mt.2010.53_bib11","doi-asserted-by":"crossref","first-page":"6733","DOI":"10.1128\/IAI.72.11.6733-6737.2004","article-title":"In vitro and in vivo evaluation of staphylococcal superantigen peptide antagonists","volume":"72","author":"Rajagopalan","year":"2004","journal-title":"Infect Immun"},{"key":"10.1038\/mt.2010.53_bib12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0896-8411(03)00120-3","article-title":"Characterization of HLA DR2 and DQ8 transgenic mouse with a new engineered mouse class II deletion, which lacks all endogenous class II genes","volume":"21","author":"Cheng","year":"2003","journal-title":"J Autoimmun"},{"issue":"Suppl 3","key":"10.1038\/mt.2010.53_bib13","doi-asserted-by":"crossref","first-page":"iii75","DOI":"10.1136\/ard.2006.058438","article-title":"Use of cell permeable NBD peptides for suppression of inflammation","volume":"65","author":"Strickland","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1038\/mt.2010.53_bib14","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/blood-2009-01-199604","article-title":"Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells","volume":"114","author":"Hideshima","year":"2009","journal-title":"Blood"},{"key":"10.1038\/mt.2010.53_bib15","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1002\/eji.1830191131","article-title":"Different staphylococcal enterotoxins bind preferentially to distinct major histocompatibility complex class II isotypes","volume":"19","author":"Herrmann","year":"1989","journal-title":"Eur J Immunol"},{"key":"10.1038\/mt.2010.53_bib16","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/intimm\/dxf047","article-title":"Staphylococcal enterotoxin B-induced activation and concomitant resistance to cell death in CD28-deficient HLA-DQ8 transgenic mice","volume":"14","author":"Rajagopalan","year":"2002","journal-title":"Int Immunol"},{"key":"10.1038\/mt.2010.53_bib17","first-page":"1153","article-title":"Jaks, STATs, cytokines, and sepsis","volume":"9","author":"Scott","year":"2002","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1038\/mt.2010.53_bib18","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1182\/blood-2005-05-2118","article-title":"Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines","volume":"107","author":"Blanco","year":"2006","journal-title":"Blood"},{"key":"10.1038\/mt.2010.53_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1146\/annurev.med.57.042905.122625","article-title":"Bortezomib: proteasome inhibition as an effective anticancer therapy","volume":"57","author":"Richardson","year":"2006","journal-title":"Annu Rev Med"},{"key":"10.1038\/mt.2010.53_bib20","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1002\/eji.200838413","article-title":"Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation","volume":"38","author":"Fissolo","year":"2008","journal-title":"Eur J Immunol"},{"key":"10.1038\/mt.2010.53_bib21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00109-003-0422-2","article-title":"Proteasome inhibition: a new anti-inflammatory strategy","volume":"81","author":"Elliott","year":"2003","journal-title":"J Mol Med"},{"key":"10.1038\/mt.2010.53_bib22","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.4049\/jimmunol.171.3.1515","article-title":"The proteasome as a lipopolysaccharide-binding protein in macrophages: differential effects of proteasome inhibition on lipopolysaccharide-induced signaling events","volume":"171","author":"Qureshi","year":"2003","journal-title":"J Immunol"},{"key":"10.1038\/mt.2010.53_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.175.1.91","article-title":"T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor","volume":"175","author":"Miethke","year":"1992","journal-title":"J Exp Med"},{"key":"10.1038\/mt.2010.53_bib24","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1172\/JCI113540","article-title":"Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits","volume":"81","author":"Mathison","year":"1988","journal-title":"J Clin Invest"},{"issue":"2 suppl. 1","key":"10.1038\/mt.2010.53_bib25","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1002\/hep.21062","article-title":"Apoptosis and necrosis in the liver: a tale of two deaths?","volume":"43","author":"Malhi","year":"2006","journal-title":"Hepatology"},{"key":"10.1038\/mt.2010.53_bib26","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.bcp.2006.07.003","article-title":"Mechanisms of crosstalk between TNF-induced NF-kappaB and JNK activation in hepatocytes","volume":"72","author":"Wullaert","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1038\/mt.2010.53_bib27","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1210\/er.2006-0031","article-title":"Hepatic tumor necrosis factor signaling and nuclear factor-kappaB: effects on liver homeostasis and beyond","volume":"28","author":"Wullaert","year":"2007","journal-title":"Endocr Rev"},{"key":"10.1038\/mt.2010.53_bib28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0092-8674(03)00521-X","article-title":"Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes","volume":"114","author":"Micheau","year":"2003","journal-title":"Cell"},{"key":"10.1038\/mt.2010.53_bib29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/376167a0","article-title":"Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B","volume":"376","author":"Beg","year":"1995","journal-title":"Nature"},{"key":"10.1038\/mt.2010.53_bib30","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1172\/JCI0215295","article-title":"Hepatocyte-specific inhibition of NF-kappaB leads to apoptosis after TNF treatment, but not after partial hepatectomy","volume":"110","author":"Chaisson","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1038\/mt.2010.53_bib31","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.canlet.2008.03.016","article-title":"Contradictory functions of NF-kappaB in liver physiology and cancer","volume":"267","author":"Vainer","year":"2008","journal-title":"Cancer Lett"},{"key":"10.1038\/mt.2010.53_bib32","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S0006-2952(03)00491-X","article-title":"Nuclear factor-kappa B plays a central role in tumour necrosis factor-mediated liver disease","volume":"66","author":"Heyninck","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1038\/mt.2010.53_bib33","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1053\/j.gastro.2007.03.045","article-title":"Hepatocyte-specific IKK gamma\/NEMO expression determines the degree of liver injury","volume":"132","author":"Beraza","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1038\/mt.2010.53_bib34","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jhep.2009.04.016","article-title":"The peptidyl-prolyl isomerase, Pin1, facilitates NF-kappaB binding in hepatocytes and protects against hepatic ischemia\/reperfusion injury","volume":"51","author":"Kuboki","year":"2009","journal-title":"J Hepatol"},{"key":"10.1038\/mt.2010.53_bib35","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/hep.21036","article-title":"Proteasome inhibition induces hepatic stellate cell apoptosis","volume":"43","author":"Anan","year":"2006","journal-title":"Hepatology"},{"key":"10.1038\/mt.2010.53_bib36","doi-asserted-by":"crossref","first-page":"G709","DOI":"10.1152\/ajpgi.00126.2006","article-title":"Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse","volume":"291","author":"Anan","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1038\/mt.2010.53_bib37","doi-asserted-by":"crossref","first-page":"21400","DOI":"10.1074\/jbc.M411952200","article-title":"NF-kappaB and not the MAPK signaling pathway regulates GADD45beta expression during acute inflammation","volume":"280","author":"Zhang","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2010.53_bib38","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/ni0503-416","article-title":"Caspase-independent cell death in T lymphocytes","volume":"4","author":"J\u00e4\u00e4ttel\u00e4","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1038\/mt.2010.53_bib39","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.cell.2009.05.021","article-title":"Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha","volume":"137","author":"He","year":"2009","journal-title":"Cell"},{"key":"10.1038\/mt.2010.53_bib40","doi-asserted-by":"crossref","first-page":"L994","DOI":"10.1152\/ajplung.90404.2008","article-title":"Effect of proteasome inhibitors on endotoxin-induced diaphragm dysfunction","volume":"296","author":"Supinski","year":"2009","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1038\/mt.2010.53_bib41","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/hep.20807","article-title":"Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL","volume":"42","author":"Ganten","year":"2005","journal-title":"Hepatology"},{"key":"10.1038\/mt.2010.53_bib42","doi-asserted-by":"crossref","first-page":"11121","DOI":"10.1074\/jbc.M806268200","article-title":"Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase\/Akt pathway","volume":"284","author":"Chen","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2010.53_bib43","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nm1763","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis","volume":"14","author":"Neubert","year":"2008","journal-title":"Nat Med"},{"key":"10.1038\/mt.2010.53_bib44","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.4049\/jimmunol.176.8.4757","article-title":"Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade)","volume":"176","author":"Schumacher","year":"2006","journal-title":"J Immunol"},{"key":"10.1038\/mt.2010.53_bib45","doi-asserted-by":"crossref","first-page":"8545","DOI":"10.1074\/jbc.273.15.8545","article-title":"Lactacystin, proteasome function, and cell fate","volume":"273","author":"Fenteany","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2010.53_bib46","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/46.5.673","article-title":"Proteasome inhibition measurements: clinical application","volume":"46","author":"Lightcap","year":"2000","journal-title":"Clin Chem"},{"key":"10.1038\/mt.2010.53_bib47","first-page":"636, 638","article-title":"[Bortezomib (Velcade) in relapsed\/refractory multiple myeloma\u2013the first experience in the Czech Republic]","volume":"144","author":"Spicka","year":"2005","journal-title":"Cas Lek Cesk"},{"key":"10.1038\/mt.2010.53_bib48","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/archinte.165.4.464","article-title":"Bortezomib-induced severe hepatitis in multiple myeloma: a case report","volume":"165","author":"Rosi\u00f1ol","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1038\/mt.2010.53_bib49","first-page":"153","article-title":"Ubiquitin-independent degradation of proteins by the proteasome","volume":"1786","author":"Jariel-Encontre","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1038\/mt.2010.53_bib50","first-page":"1419","article-title":"Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma","volume":"7","author":"Sunwoo","year":"2001","journal-title":"Clin Cancer Res"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500161631053X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500161631053X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T21:40:29Z","timestamp":1740001229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500161631053X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S152500161631053X"],"URL":"https:\/\/doi.org\/10.1038\/mt.2010.53","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detrimental Effect of the Proteasome Inhibitor, Bortezomib in Bacterial Superantigen- and Lipopolysaccharide-induced Systemic Inflammation","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/mt.2010.53","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}